Preoperative serum levels of early prostate cancer antigen (EPCA) predict prostate cancer progression in patients undergoing radical prostatectomy

Prostate

Volumn 72, Issue 3, 2012, Pages 270-279

  Zhao, Zhigang ^a   Ma, Wenjing ^a   Zeng, Guohua ^a   Qi, Defeng ^a   Ou, Lili ^a   Liang, Yeping ^a  

^a Minimally Invasive Surgery Center   (China)

Author keywords

early prostate cancer antigen (EPCA); prognosis; prostate cancer (PCa); radical prostatectomy (RP)

Indexed keywords

EARLY PROSTATE CANCER ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HAZARD RATIO; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, NEOPLASM; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84855643877     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21428     Document Type: Article

References (34)

1. Cooperberg MR, Moul JW, Carroll PR,. The changing face of prostate cancer. J Clin Oncol 2005; 23: 8146-8151. (Pubitemid 46211547)
2. Simmons MN, Stephenson AJ, Klein EA,. Natural history of biochemical recurrence after radical prostatectomy: Risk assessment for secondary therapy. Eur Urol 2007; 51: 1175-1184. (Pubitemid 46436320)
3. Sandler HM, Eisenberger MA,. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy. J Urol 2007; 178: S20-S24. (Pubitemid 47211166)
4. Dhir R, Vietmeier B, Arlotti J, Acquafondata M, Landsittel D, Masterson R, Getzenberg RH,. Early identification of individuals with prostate cancer in negative biopsies. J Urol 2004; 171: 1419-1423. (Pubitemid 38365385)
5. Paul B, Dhir R, Landsittel D, Hitchens MR, Getzenberg RH,. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res 2005; 65: 4097-4100. (Pubitemid 40775646)
6. Zhao Z, Zeng G,. Increased serum level of early prostate cancer antigen (EPCA) is associated with subsequent cancer risk in men with high grade prostatic intraepithelial neoplasia. Endocr Relat Cancer 2010; 17: 505-512.
7. Zhao Z, Zeng G, Zhong W,. Serum early prostate cancer antigen (EPCA) as a significant predictor of incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia. Prostate 2010; 70: 1788-1798.
8. Greene FL, Page DL, Fleming ID,. AJCC Cancer Staging Manual. 6th edition. New York: Springer-Verlag; 2002.
9. Gleason DF, Mellinger GT, The Veterans Administrative Cooperative Urologic Research Group. Histologic grading and clinical staging of prostatic carcinoma. In:, Tannenbaum M, editor. Urologic pathology: The Prostate. Philadelphia: Lea & Febiger; 1998. pp. 171-198.
10. Smith DS, Catalona WJ, Herschman JD,. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996; 276: 1309-1315. (Pubitemid 26346930)
11. Cannon GM, Walsh PC, Partin AW, Pound CR,. Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer. J Urol 2003; 62: 2-8. (Pubitemid 41116558)
12. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW,. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-439. (Pubitemid 41124175)
13. Shariat SF, Kattan MW, Song W, Bernard D, Gottenger E, Wheeler TM, Slawin KM,. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Cancer Res 2003; 63: 5874-5878. (Pubitemid 37187487)
14. Svatek RS, Karam JA, Roehrborn CG, Karakiewicz PI, Slawin KM, Shariat SF,. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clin Cancer Res 2008; 14: 3362-3366.
15. Kattan MW, Fearn PA, Leibel S, Potters L,. The definition of biochemical failure in patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 2000; 48: 1469-1474.
16. Leventis A, Shariat S, Kattan M, Butler EB, Wheeler TM, Slawin KM,. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2001; 19: 1030-1039. (Pubitemid 32176278)
17. Uetsuki H, Tsunemori H, Taoka R, Haba R, Ishikawa M, Kakehi Y,. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. J Urol 2005; 174: 514-518. (Pubitemid 40981588)
18. Wheeler TM,. Anatomic considerations in carcinoma of the prostate. Urol Clin North Am 1989; 16: 623-634. (Pubitemid 19277264)
19. Yossepowitch O, Bjartell A, Eastham JA, Graefen M, Guillonneau BD, Karakiewicz PI, Montironi R, Montorsi F,. Positive surgical margins in radical prostatectomy: Outlining the problem and its long-term consequences. Eur Urol 2009; 55: 87-99.
20. Jansen FH, Roobol M, Jenster G, Schröder FH, Bangma CH,. Screening for Prostate Cancer in 2008 II: The importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Eur Urol 2009; 55: 563-574.
21. Crawford ED, Abrahamsson PA,. PSA-based screening for prostate cancer: How does it compare with other cancer screening tests? Eur Urol 2008; 54: 262-273.
22. Schröder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH, Roobol MJ,. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol 2008; 53: 468-477. (Pubitemid 351179007)
23. Bickers B, Aukim-Hastie C,. New molecular biomarkers for the prognosis and management of prostate cancer-The post PSA era. Anticancer Res 2009; 29: 3289-3298.
24. Steuber T, O'Brien MF, Lilja H,. Serum markers for prostate cancer: A rational approach to the literature. Eur Urol 2008; 54: 31-40.
25. Schalken JA, Bergh A, Bono A, Foster C, Gospadarowicz M, Isaacs WB, Rubin M, Schröder F, Tribukait B, Tsukamotot T, Wiklund P,. Molecular prostate cancer pathology: Current issues and achievements. Scand J Urol Nephrol Suppl 2005; 216: 82-93.
26. Stamey TA,. Preoperative serum prostate-specific antigen (PSA) below 10microg/l predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure. Clin Chem 2001; 47: 631-634. (Pubitemid 32275804)
27. Smith RC, Partin AW, Epstein JI, Brendler CB,. Extended followup of the influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer and extensive capsular perforation. J Urol 1996; 156: 454-457.
28. Miyake H, Fujimoto H, Komiyama M, Fujisawa M,. Development of "extended radical retropubic prostatectomy": A surgical technique for improving margin positive rates in prostate cancer. Eur J Surg Oncol 2010; 36: 281-286.
29. Melchior SW, Corey E, Ellis WJ, Ross AA, Layton TJ, Oswin MM, Lange PH, Vessella RL,. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res 1997; 3: 249-256. (Pubitemid 27107302)
30. Slawin KM, Shariat SF, Nguyen C, Leventis AK, Song W, Kattan MW, Young CY, Tindall DJ, Wheeler TM,. Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein. Cancer Res 2000; 60: 7142-7148. (Pubitemid 32059196)
31. Zink D, Fischer AH, Nickerson JA,. Nuclear structure in cancer cells. Nat Rev Cancer 2004; 9: 677-687. (Pubitemid 39215066)
32. Inoue T, Leman ES, Yeater DB, Getzenberg RH,. The potential role of purine-rich element binding protein (PUR) alpha as a novel treatment target for hormone-refractory prostate cancer. Prostate 2008; 68: 1048-1056. (Pubitemid 351875176)
33. Coradeghini R, Barboro P, Rubagotti A, Boccardo F, Parodi S, Carmignani G, D'Arrigo C, Patrone E, Balbi C,. Differential expression of nuclear lamins in normal and cancerous prostate tissues. Oncol Rep 2006; 15: 609-613.
34. Barboro P, Rubagotti A, Boccardo F, Carnemolla B, Darrigo C, Patrone E, Balbi C,. Nuclear matrix protein expression in prostate cancer: Possible prognostic and diagnostic applications. Anticancer Res 2005; 25: 3999-4004. (Pubitemid 41665177)